Clinical trialNCT05922878RecruitingPhase 2Interventional

Study of ALTO-300 in MDD

SponsorAlto NeuroscienceEnrollment321Major Depressive Disorder

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to determine efficacy differences between ALTO-300 and placebo, used adjunctively to an antidepressant, related to patient characteristics.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Adam Savitz, MD, PhD
Alto Neuroscience
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

45 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Site 189
Phoenix, Arizona, United States
Withdrawn
Site 200
Phoenix, Arizona, United States
Recruiting
Site 187
Yuma, Arizona, United States
Recruiting
Site 193
Rogers, Arkansas, United States
Recruiting
Site 218
Bellflower, California, United States
Recruiting
Site 217
Glendale, California, United States
Recruiting
Site 335
Lafayette, California, United States
Recruiting
Site 209
Los Angeles, California, United States
Recruiting
Site 219
Mather, California, United States
Recruiting
Site 194
Mission Viejo, California, United States
Recruiting
Site 197
Temecula, California, United States
Recruiting
Site 203
Colorado Springs, Colorado, United States
Recruiting
Site 349
Evergreen, Colorado, United States
Recruiting
Site 214
Norwalk, Connecticut, United States
Recruiting
Site 159
Clermont, Florida, United States
Recruiting
Site 225
Miami Gardens, Florida, United States
Recruiting
Site 190
Miami Lakes, Florida, United States
Recruiting
Site 161
Okeechobee, Florida, United States
Recruiting
Site 221
Tampa, Florida, United States
Recruiting
Site 220
West Palm Beach, Florida, United States
Recruiting
Site 224
Savannah, Georgia, United States
Recruiting
Site 208
Snellville, Georgia, United States
Recruiting
Site 119
Boise, Idaho, United States
Recruiting
Site 310
Chicago, Illinois, United States
Recruiting
Site 201
Marrero, Louisiana, United States
Terminated
Site 198
Monroe, Louisiana, United States
Terminated
Site 215
Jackson, Mississippi, United States
Recruiting
Site 344
Las Vegas, Nevada, United States
Recruiting
Site 114
Albuquerque, New Mexico, United States
Recruiting
Site 191
Rochester, New York, United States
Terminated
Site 192
Staten Island, New York, United States
Recruiting
Site 199
Hickory, North Carolina, United States
Recruiting
Site 202
Cincinnati, Ohio, United States
Recruiting
Site 195
Oklahoma City, Oklahoma, United States
Recruiting
Site 216
Allentown, Pennsylvania, United States
Recruiting
Site 350
Media, Pennsylvania, United States
Recruiting
Site 352
Moosic, Pennsylvania, United States
Recruiting
Site 102
Dallas, Texas, United States
Withdrawn
Site 148
Fort Worth, Texas, United States
Withdrawn
Site 347
Fort Worth, Texas, United States
Recruiting

5 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

ALTO-300Placebo

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 8 Jun 2023
Primary completion: 31 Dec 2026
Completion: 31 Dec 2026
Last update posted: 24 Jul 2025
Registered enrollment: 321
Registry id: NCT05922878

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.